1. Home
  2. EVAC vs SIGA Comparison

EVAC vs SIGA Comparison

Compare EVAC & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EVAC
  • SIGA
  • Stock Information
  • Founded
  • EVAC 2024
  • SIGA 1995
  • Country
  • EVAC United States
  • SIGA United States
  • Employees
  • EVAC N/A
  • SIGA N/A
  • Industry
  • EVAC Fluid Controls
  • SIGA Biotechnology: Pharmaceutical Preparations
  • Sector
  • EVAC Industrials
  • SIGA Health Care
  • Exchange
  • EVAC Nasdaq
  • SIGA Nasdaq
  • Market Cap
  • EVAC 591.4M
  • SIGA 594.3M
  • IPO Year
  • EVAC 2025
  • SIGA 1997
  • Fundamental
  • Price
  • EVAC $10.04
  • SIGA $5.86
  • Analyst Decision
  • EVAC
  • SIGA
  • Analyst Count
  • EVAC 0
  • SIGA 0
  • Target Price
  • EVAC N/A
  • SIGA N/A
  • AVG Volume (30 Days)
  • EVAC 77.5K
  • SIGA 426.1K
  • Earning Date
  • EVAC 01-01-0001
  • SIGA 11-06-2025
  • Dividend Yield
  • EVAC N/A
  • SIGA 10.17%
  • EPS Growth
  • EVAC N/A
  • SIGA N/A
  • EPS
  • EVAC N/A
  • SIGA 1.03
  • Revenue
  • EVAC N/A
  • SIGA $172,249,641.00
  • Revenue This Year
  • EVAC N/A
  • SIGA N/A
  • Revenue Next Year
  • EVAC N/A
  • SIGA $115.06
  • P/E Ratio
  • EVAC N/A
  • SIGA $5.73
  • Revenue Growth
  • EVAC N/A
  • SIGA N/A
  • 52 Week Low
  • EVAC $9.90
  • SIGA $4.95
  • 52 Week High
  • EVAC $10.17
  • SIGA $9.62
  • Technical
  • Relative Strength Index (RSI)
  • EVAC N/A
  • SIGA 20.22
  • Support Level
  • EVAC N/A
  • SIGA $6.20
  • Resistance Level
  • EVAC N/A
  • SIGA $8.46
  • Average True Range (ATR)
  • EVAC 0.00
  • SIGA 0.34
  • MACD
  • EVAC 0.00
  • SIGA -0.22
  • Stochastic Oscillator
  • EVAC 0.00
  • SIGA 1.15

About EVAC EQV Ventures Acquisition Corp. II Class A Ordinary Shares

EQV Ventures Acquisition Corp II is a blank check company.

About SIGA SIGA Technologies Inc.

SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.

Share on Social Networks: